Announcements Trials
Browse Landscape

Phase

Phase 2 148Phase 1 62Phase 1/2 61Phase 3 52Phase 2/3 9Phase NA 4Phase EARLY_PHASE1 4Phase 4 3

Status

Terminated 4Recruiting 4Unknown 3Completed 2Withdrawn 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Lymphoma, B-Cell 1Glioma 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Carboplatin × Clear all
NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

NCT02279992 2017-09-11

LevitraCarbo

Cedars-Sinai Medical Center

Phase EARLY_PHASE1 Terminated
7 enrolled
CNS

Brain Neoplasms, Glioma

NCT02319889 2017-02-01

Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00515138 2012-04-12

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

University of California, San Francisco

Phase EARLY_PHASE1 Terminated
7 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡